Sammartano Vincenzo, Franceschini Marta, Fredducci Sara, Caroni Federico, Ciofini Sara, Pacelli Paola, Bocchia Monica, Gozzetti Alessandro
Department of Medicine, Surgery and Neuroscience, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena 53100, Italy.
Authors share last co-authorship.
Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. eCollection 2023.
Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.
多发性骨髓瘤治疗的最新进展提高了缓解深度并最终延长了生存期；然而，预后仍然很差。BCMA抗原在骨髓瘤细胞中高度表达，因此是新型疗法的一个靶点。目前有几种或正在研发几种通过不同机制靶向BCMA的药物，包括双特异性T细胞衔接器、与抗体偶联的药物以及嵌合抗原受体T细胞（CAR-T细胞）。靶向BCMA的免疫疗法在先前接受过多种治疗的多发性骨髓瘤患者中已显示出良好的疗效和安全性。本综述将讨论骨髓瘤中抗BCMA靶向治疗的最新进展，特别关注目前可用的药物。
